IOBT IO Biotech
- 1.410
- -0.020-1.40%
- 1.380
- -0.030-2.13%
IO Biotech News
Form 144 | IO Biotech(IOBT.US) 10% Stockholder Proposes to Sell 988.21K in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $IO Biotech(IOBT.US)$ 10% Stockholder Novo Holdings A/S intends to sell 658.81K shares of its common stock on May 10, with a total market value of approximately $988.21
IO Biotech Board Member Jack Nielsen Resigns Due to Health
IO Biotech Presents New Data For Cancer Vaccine Candidate, IO102-IO103, At AACR 2024
IO Biotech Presents New Data For Cancer Vaccine Candidate, IO102-IO103, At AACR 2024
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech (Nasdaq: IOBT) today shared new data related to the company's lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
IO Biotech: Miyara Will Be Based in the US, Reporting to CEO, Mai-Britt Zocca >IOBT
IO Biotech: Miyara Will Be Based in the US, Reporting to CEO, Mai-Britt Zocca >IOBT
IO Biotech Appoints Faical Miyara Chief Business Officer >IOBT
IO Biotech Appoints Faical Miyara Chief Business Officer >IOBT
IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersSCWorx (NASDAQ:WORX) stock increased by 60.8% to $2.75 during Wednesday's after-market session. The market value of their outstanding shares is at $3.3 million. IO Biotech (NASDAQ:IOBT) stock i
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage
HC Wainwright & Co. Reiterates Buy on IO Biotech, Maintains $8 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates IO Biotech with a Buy and maintains $8 price target.
IO Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 393.83% HC Wainwright & Co. → $8 Reiterates Buy → Buy 09/28/2023 517.28% Piper Sandler → $10 In
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and IO Biotech (IOBT)
Buy Recommendation for IO Biotech on Strong Data Prospects and Undervalued Stock Position
IO Biotech GAAP EPS of -$0.40 Misses by $0.02
IO Biotech Q4 EPS $(0.40) Misses $(0.39) Estimate
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.39) by 2.56 percent. This is a 42.03 percent increase over losses of $(0.69)
IO Biotech 4Q Loss $26.2M >IOBT
IO Biotech 4Q Loss $26.2M >IOBT
IO Biotech 4Q Loss/Shr 40c >IOBT
IO Biotech 4Q Loss/Shr 40c >IOBT
IO Biotech Sees Operational Runway Into 4Q of 2025 >IOBT
IO Biotech Sees Operational Runway Into 4Q of 2025 >IOBT
Press Release: IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results -- Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination
IO Biotech to Present at 44th Annual Cowen Health Care Conference
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win platform,
Analysis
Price Target
No Data
